Literature DB >> 26045595

Survival in patients with familial and sporadic myeloproliferative neoplasms.

Malin Hultcrantz1, Sigrún H Lund2, Ola Landgren3, Jan Samuelsson4, Lynn R Goldin5, Asmundur Oddsson6, Magnus Björkholm1, Sigurdur Y Kristinsson7.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 26045595      PMCID： PMC4458805          DOI： 10.1182/blood-2015-04-639039

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  9 in total

1.  Somatic mutations in calreticulin can be found in pedigrees with familial predisposition to myeloproliferative neoplasms.

Authors:  Pontus Lundberg; Ronny Nienhold; Achille Ambrosetti; Francisco Cervantes; Manuel M Pérez-Encinas; Radek C Skoda
Journal:  Blood       Date:  2014-04-24       Impact factor: 22.113

2.  Long term follow up of 93 families with myeloproliferative neoplasms: life expectancy and implications of JAK2V617F in the occurrence of complications.

Authors:  Sandra Malak; Myriam Labopin; Cecile Saint-Martin; Christine Bellanne-Chantelot; Albert Najman
Journal:  Blood Cells Mol Dis       Date:  2012-07-19       Impact factor: 3.039

3.  Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study.

Authors:  Malin Hultcrantz; Sigurdur Yngvi Kristinsson; Therese M-L Andersson; Ola Landgren; Sandra Eloranta; Asa Rangert Derolf; Paul W Dickman; Magnus Björkholm
Journal:  J Clin Oncol       Date:  2012-07-16       Impact factor: 44.544

4.  The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms.

Authors:  Damla Olcaydu; Elisa Rumi; Ashot Harutyunyan; Francesco Passamonti; Daniela Pietra; Cristiana Pascutto; Tiina Berg; Roland Jäger; Emma Hammond; Mario Cazzola; Robert Kralovics
Journal:  Haematologica       Date:  2010-12-20       Impact factor: 9.941

5.  Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation.

Authors:  Elisa Rumi; Francesco Passamonti; Matteo G Della Porta; Chiara Elena; Luca Arcaini; Laura Vanelli; Cecilia Del Curto; Daniela Pietra; Emanuela Boveri; Cristiana Pascutto; Mario Cazzola; Mario Lazzarino
Journal:  J Clin Oncol       Date:  2007-11-12       Impact factor: 44.544

6.  Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden.

Authors:  Ola Landgren; Lynn R Goldin; Sigurdur Y Kristinsson; Elin A Helgadottir; Jan Samuelsson; Magnus Björkholm
Journal:  Blood       Date:  2008-05-01       Impact factor: 22.113

7.  JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms.

Authors:  Amy V Jones; Andrew Chase; Richard T Silver; David Oscier; Katerina Zoi; Y Lynn Wang; Holger Cario; Heike L Pahl; Andrew Collins; Andreas Reiter; Francis Grand; Nicholas C P Cross
Journal:  Nat Genet       Date:  2009-03-15       Impact factor: 38.330

8.  CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis.

Authors:  Elisa Rumi; Ashot S Harutyunyan; Daniela Pietra; Jelena D Milosevic; Ilaria C Casetti; Marta Bellini; Nicole C C Them; Chiara Cavalloni; Virginia V Ferretti; Chiara Milanesi; Tiina Berg; Emanuela Sant'Antonio; Emanuela Boveri; Cristiana Pascutto; Cesare Astori; Robert Kralovics; Mario Cazzola
Journal:  Blood       Date:  2014-02-19       Impact factor: 22.113

9.  The germline sequence variant rs2736100_C in TERT associates with myeloproliferative neoplasms.

Authors:  A Oddsson; S Y Kristinsson; H Helgason; D F Gudbjartsson; G Masson; A Sigurdsson; A Jonasdottir; A Jonasdottir; H Steingrimsdottir; B Vidarsson; S Reykdal; G I Eyjolfsson; I Olafsson; P T Onundarson; G Runarsson; O Sigurdardottir; A Kong; T Rafnar; P Sulem; U Thorsteinsdottir; K Stefansson
Journal:  Leukemia       Date:  2014-01-30       Impact factor: 11.528
  9 in total
  2 in total

Review 1.  From leeches to personalized medicine: evolving concepts in the management of polycythemia vera.

Authors:  Alessandro M Vannucchi
Journal:  Haematologica       Date:  2016-11-24       Impact factor: 9.941

2.  Familial essential thrombocythemia: 6 cases from a mono-institutional series.

Authors:  Vincenzo Accurso; Marco Santoro; Salvatrice Mancuso; Giorgia Vajana; Riccardo Tomasello; Cristina Rotolo; Giulia Camarda; Marta Mattana; Sergio Siragusa
Journal:  Clin Case Rep       Date:  2022-03-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.